BIOMAT Database Logo BIOMAT Database Logo

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. 2001

J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK.

OBJECTIVE Meta-iodo-benzyl-guanidine labelled with 131-iodine [(131)I-mIBG] has been used extensively for imaging tumours originating from the neural crest but experience with its therapeutic use is limited, particularly for non-catecholamine secreting tumours. In order to assess the therapeutic response and potential adverse effects of the therapeutic administration of (131)I-mIBG, we have reviewed all patients who had received this form of treatment in our department. METHODS Retrospective analysis of the case notes of patients with neuroendocrine tumours who received treatment with (131)I-mIBG and were followed-up according to a defined protocol in a given time frame. METHODS Thirty-seven patients (18 with metastatic carcinoid tumours, 8 metastatic phaeochromocytoma, 7 metastatic paraganglioma and 4 metastatic medullary carcinoma of the thyroid) treated with (131)I-mIBG over a 15-year period were included in this analysis. METHODS The symptomatic, hormonal and tumoural responses before and after (131)I-mIBG therapy over a median follow-up duration of 32 months (range 5-180 months) were recorded. Of the 37 patients (22 males; median age 51 years, range 18-81 years), 15 were treated with (131)I-mIBG alone whereas the other 22 received additional therapy. RESULTS A total of 116 therapeutic (131)I-mIBG doses were administered [mean cumulative dose 592 mCi (21.9 GBq); range 200-1592 mCi (7.4-58.9 GBq)]. None of the patients showed a complete tumour response. However, 82% of patients treated with (131)I-mIBG alone and 84% who received additional therapy showed stable disease over the period of follow-up. Overall survival during the period of the study was 71%. The overall 5-year survival rate was 85% (95% confidence interval, 72-99%) for all patients and 78% (95% confidence interval, 55-100%) for the carcinoid group alone, according to Kaplan-Meier analysis. Symptomatic control was achieved in all the patients treated with (131)I-mIBG alone, and in 72% of those receiving additional therapy. Hormonal control was noted in 50% and 57% of patients, respectively. (131)I-mIBG therapy was safe and well tolerated. Serious side-effects necessitating the termination of (131)I-mIBG therapy were seen in only 2 of our patients. CONCLUSIONS (131)I-mIBG therapy produces symptomatic and hormonal improvement and moderate tumour regression/stabilization in patients with metastatic neuroendocrine tumours with minimal adverse effects. It may be a valuable alternative or additional therapeutic option to the currently available conventional treatment modalities.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010235 Paraganglioma A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992) Paraganglioma, Gangliocytic,Paragangliomata,Gangliocytic Paraganglioma,Gangliocytic Paragangliomas,Paragangliomas,Paragangliomatas
D010673 Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) Pheochromocytoma, Extra-Adrenal,Extra-Adrenal Pheochromocytoma,Extra-Adrenal Pheochromocytomas,Pheochromocytoma, Extra Adrenal,Pheochromocytomas,Pheochromocytomas, Extra-Adrenal
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D002276 Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182) Argentaffinoma,Carcinoid,Carcinoid, Goblet Cell,Argentaffinomas,Carcinoid Tumors,Carcinoids,Carcinoids, Goblet Cell,Goblet Cell Carcinoid,Goblet Cell Carcinoids,Tumor, Carcinoid,Tumors, Carcinoid
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
Use of 131 I-MIBG therapy in MIBG-positive metastatic medullary thyroid carcinoma.
June 2012, Thyroid : official journal of the American Thyroid Association,
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
Iodine-131 meta-iodobenzylguanidine (131I-MIBG) for the localization of suspected phaeochromocytoma.
July 1989, Nuclear medicine communications,
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
[131-I-MIBG and sporadic medullary carcinoma of the thyroid].
February 1987, Revista clinica espanola,
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
Detection of medullary carcinoma of the thyroid with I-131 MIBG.
December 1994, Clinical nuclear medicine,
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
Side effects of treatment with I-131-meta-iodobenzylguanidine (I-131-MIBG) in neuroblastoma patients.
January 1988, Progress in clinical and biological research,
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.
April 2014, Clinical endocrinology,
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
False diagnosis of bilateral phaeochromocytoma by iodine-131-labelled meta-iodobenzylguanidine (MIBG)
January 1984, Lancet (London, England),
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
I-131 MIBG detection of metastatic hepatic carcinoid.
August 1994, Clinical nuclear medicine,
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
Medullary thyroid carcinoma: localization of a mediastinal metastasis with I-131 MIBG.
August 1988, Clinical nuclear medicine,
J J Mukherjee, and G A Kaltsas, and N Islam, and P N Plowman, and R Foley, and J Hikmat, and K E Britton, and P J Jenkins, and S L Chew, and J P Monson, and G M Besser, and A B Grossman
Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
May 2015, QJM : monthly journal of the Association of Physicians,
Copied contents to your clipboard!